protein kinase c

Protein Kinase C (19-31) TFA, a peptide inhibitor of protein kinase C (PKC), derived from the pseudo-substrate regulatory domain of PKCa (residues 19-31) with a serine at position 25 replacing the wild-type alanine, is used as protein kinase C substrate peptide for testing the protein kinase C activity.

Protein Kinase C (19-31), a peptide inhibitor derived from the pseudo-substrate regulatory domain of PKCa (residues 19-31) with a serine at position 25 replacing the wild-type alanine, is used as a substrate peptide for testing protein kinase C activity.

Protein Kinase C (19-36) is a synthetic peptide inhibitor based on the pseudosubstrate domain of protein kinase C. It selectively blocks PKC activity by binding to the substrate-binding site, demonstrating potent inhibition at sub-micromolar concentrations (IC₅₀ ~0.1 μM). This compound is widely used in kinase signaling research to validate PKC involvement in cellular processes, including synaptic plasticity studies where it substantially reduces phosphorylation of PKC substrates in hippocampal preparations. Ideal for use in cell-free assays, electrophysiology experiments, and kinase activity profiling to elucidate PKC-dependent pathways.

Protein Kinase C 19-31 acetate, a peptide inhibitor of protein kinase C (PKC), derived from the pseudo-substrate regulatory domain of PKCa (residues 19-31) with a serine at position 25 replacing the wild-type alanine, is used as protein kinase C substrate

Protein Kinase C substrate, a specific substrate of Protein Kinase C, plays a pivotal role in signal transduction by facilitating the detection of protein through its enzyme's catalytic action on specific substrate phosphorylation ^[1].

Protein Kinase C (alpha) Peptide (TFA) is a PKC-α-associated peptide functioning as a lipid-dependent serine/threonine protein kinase. It plays a pivotal role in regulating several cellular functions such as survival, proliferation, differentiation, migration, and adhesion ^[1].

Protein Kinase C (gamma) Peptide, a fragment of Protein Kinase Cγ, plays a role in dominant ataxia by inhibiting the nuclear import of aprataxin, which is associated with recessive ataxia ^[1].

Protein Kinase C (beta) Peptide, a fragment of Protein Kinase Cβ, is associated with hyperglycemia-induced decreases in endothelium-derived nitric oxide. Inhibiting Protein Kinase Cβ forestalls the impairment of endothelium-dependent vasodilation caused by acute hyperglycemia ^[1].

Protein Kinase C (661-671), a fragment peptide of the β1 subspecies of Protein Kinase C (PKC), is instrumental in regulating cellular growth and has been implicated in tumor promotion ^{[1] [2]}.

Protein Kinase C βII V5 peptide (660-673) (PKC βII (660-673)) exhibits an affinity for binding to RACK1 ^[1].

Protein Kinase C (19-35) Peptide, acting as a PKC pseudosubstrate inhibitor/region, can potentially inhibit PKC activity by blocking the substrate-binding site within the kinase domain, thereby inactivating the cytoplasmic form of PKC ^{[1] [2]}.

Protein Kinase C Peptide Substrate targets specific cell spacers ina manner that is dependent on second messengers and specific adaptor proteins in response to extracellular signals that activate g protein-coupled receptors, tyrosine Kinase receptors, or

Protein Kinase C, Rat (EC 2.7.1.37) is a type of protein kinase that regulates the function of other proteins by phosphorylating the hydroxyl groups on serine and threonine residues. This kinase can be activated by signals such as increased concentrations of diacylglycerol (DAG) or calcium ions (Ca2+).

Protein Kinase C Peptide Substrate acetate targets specific cell spacers ina manner that is dependent on second messengers and specific adaptor proteins in response to extracellular signals that activate g protein-coupled receptors, tyrosine Kinase recept

Staurosporine (AM-2282) is a protein kinase inhibitor with ATP-competitive and non-selective inhibitory activity (IC₅₀=6/15/2/3/3000 nM) against PKC, PKA, c-Fgr, phosphorylase kinase and TAOK2. Staurosporine also induces apoptosis.

Go 6983 is a PKC inhibitor with IC₅₀ values of 7, 7, 6, 10, and 60 nM for PKCα, PKCβ, PKCγ, PKCδ, and PKCζ, respectively. Go 6983 has antitumor activity, cardiovascular protection, and protein kinase C inhibition.

Bisindolylmaleimide I (GF109203X) is a potent and highly selective protein kinase C (PKC) inhibitor, exhibiting a Ki of 14 nM.

Hypericin (Cyclosan) is a natural anthraquinone compound, an extract of Hypericum perforatum, which inhibits PKC, MAO, dopamine-beta-hydroxylase, reverse transcriptase, telomerase, and CYP, etc. Hypericin exhibits antimicrobial, antiviral, antitumor, and antidepressant activities.

Phorbol 12-myristate 13-acetate (PMA) is a natural phorbol ester that acts as an activator of PKC, SphK, and NF-κB, and is commonly used to induce differentiation of THP-1 cells and establish dermatitis models.

Ionomycin calcium (SQ23377 calcium) is an effective and selective calcium ionophore, demonstrating high specificity for divalent cations (Ca>Mg>Sr=Ba).

Mitoxantrone dihydrochloride (NSC-301739) is the hydrochloride salt of an anthracenedione antibiotic with antineoplastic activity. It is a type II topoisomerase inhibitor.

Daphnetin (7,8-Dihydroxycoumarin), a natural coumarin derivative, is a protein kinase inhibitor with inhibitory for EGFR (IC₅₀: 7.67 μM), PKA (IC₅₀: 9.33 μM), and PKC (IC₅₀: 25.01 μM), also exhibit anti-oxidant and anti-inflammatory activities.

Mitoxantrone (mitozantrone) is an anthracenedione antibiotic with antineoplastic activity. Mitoxantrone intercalates into and crosslinks DNA, thereby disrupting DNA and RNA replication. This agent also binds to topoisomerase II, resulting in DNA strand breaks and inhibition of DNA repair. Mitoxantrone is less cardiotoxic compared to doxorubicin.

Bisindolylmaleimide VIII acetate (Ro 31-7549 acetate) is a potent and selective PKC inhibitor (IC₅₀: 158 nM for rat brain PKC) with IC₅₀ values of 53, 195, 163, 213, and 175 nM for PKC-α, PKC-βI, PKC-βII, PKC-γ, and PKC-ε, respectively.